From Lab Bench to Global Stage: Cancer Pioneer Dr. Morag Park to Lead Gairdner Foundation

TORONTO, ON – June 16, 2026 – The Gairdner Foundation, one of the world's most prestigious biomedical prize organizations and a noted bellwether for future Nobel laureates, has appointed Dr. Morag Park as its new President and Scientific Director. The decision, which follows a rigorous global search, places a titan of Canadian cancer research at the helm of an institution renowned for identifying the science that shapes the future of human health.

Effective June 1, 2026, Dr. Park succeeds Dr. Janet Rossant, who led the Foundation with distinction for the past decade. The appointment is more than a leadership change; it signals a strategic alignment of the Foundation’s mission with a leader whose career has been defined by both foundational scientific discovery and the architectural work of building national research ecosystems. For an organization whose awards have preceded 103 Nobel Prizes, selecting a leader is a statement of intent. In choosing Dr. Park, the Gairdner Foundation is betting on a future defined by precision, collaboration, and a relentless drive to translate discovery into impact.

A Legacy of Discovery in Precision Oncology

Dr. Park’s reputation is built on a bedrock of groundbreaking research that has fundamentally altered the understanding of cancer. Her pioneering work on the MET receptor tyrosine kinase, a key driver of tumor growth and metastasis, helped lay the scientific groundwork for a new class of targeted cancer therapies used worldwide. This research, which began during her postdoctoral training, was instrumental in characterizing the MET proto-oncogene and has since evolved into a comprehensive program exploring how these cellular signals dictate cancer’s behavior.

Her influence extends deeply into the challenging field of breast cancer, particularly triple-negative breast cancer (TNBC), an aggressive subtype with limited treatment options. Dr. Park’s lab has been at the forefront of studying the tumor microenvironment—the complex ecosystem of cells, blood vessels, and molecules surrounding a tumor. This work has illuminated how interactions within this microenvironment can drive tumor progression and resistance to therapy. To advance this research, she established Quebec’s first breast cancer tumor bank and developed innovative “living biobanks” of patient-derived tumor models, allowing scientists to study how real-world cancers respond to new treatments.

Her scientific contributions have been recognized with a cascade of honours, including the Canadian Cancer Society Robert L. Noble Prize, a fellowship in the Royal Society of Canada, and a knighthood in the Ordre national du Québec. In a timely affirmation of her impact, Dr. Park is also a 2026 inductee into the Canadian Medical Hall of Fame, a distinction that celebrates her transformative role in Canadian medicine.

Architect of Canada's Research Ecosystem

Beyond her own lab, Dr. Park has demonstrated a rare talent for systems-level leadership, shaping the very infrastructure of Canadian science. As Scientific Director of the Canadian Institutes of Health Research (CIHR) Institute of Cancer Research from 2008 to 2013, she championed national initiatives in personalized medicine and cancer prevention, pushing the system toward a more targeted and effective approach to the disease.

Perhaps most significantly, as co-chair of the Canadian Cancer Research Alliance, she orchestrated the development of Canada's first-ever Pan-Canadian Cancer Research Strategic Plan. This monumental effort required her to unite more than 30 disparate funding agencies around a common vision, a testament to her ability to build consensus and drive collaborative strategy on a national scale. This experience in navigating the complex landscape of science funding, policy, and institutional collaboration is precisely what the Gairdner Foundation requires as it seeks to expand its own global partnerships and impact.

"Dr Morag Park is exactly the scientific leader to best serve the Gairdner Foundation at this moment," said Dr. Heather Munroe-Blum, Chair of the Gairdner Foundation Board of Directors. "Her research record speaks for itself – but it is her rigorous standards and her ability to support scientists and build the systems that allow great science to flourish, that make her appointment so very exciting."

A New Era for a Nobel Predictor

Founded in 1957, the Gairdner Foundation occupies a unique space in the global scientific landscape. Its mission is to recognize transformative discoveries early, often years before they are celebrated on the world stage in Stockholm. The appointment of a leader of Dr. Park's caliber is seen by many as a move to fortify this legacy.

Dr. Park inherits a robust organization from Dr. Janet Rossant, whose tenure was marked by a significant expansion of the Foundation's outreach programs, aimed at inspiring the next generation of scientists. Dr. Rossant praised her successor, stating, "A distinguished scientist and inspiring leader, Morag combines exceptional vision, energy, and dedication to excellence. Under her leadership, I am confident that Gairdner will continue to strengthen its impact and reach new heights."

The sentiment is echoed by those whose own careers were recognized by the Foundation. "The appointment of Dr. Park, an exemplary science leader and scientist, assures the continued recognition of excellence by the Canada Gairdner Awards," noted Dr. Philip Sharp, a 1986 Gairdner laureate who went on to win the Nobel Prize in 1993.

As President and Scientific Director, Dr. Park will now steward the Foundation's internationally renowned awards program and its wide-ranging educational initiatives. Her leadership comes as the Foundation gains momentum, backed by increased government support and a clear mandate to grow its influence. In her new role, she is poised to leverage her deep expertise in both basic science and strategic policy to not only identify today's most brilliant minds but also to help foster the environment in which tomorrow's breakthroughs can occur.

Dr. Park herself views the mission with a sense of gravity and purpose. "The Gairdner Foundation exists to find the science that will matter most to human health, and to inspire the next generation of scientists to pursue it," she stated. "That mission has never felt more urgent. I am honoured to lead an organization with this extraordinary reach and an important record of recognizing excellence before the rest of the world does."